Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.

Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.

Item
http://www.wikidata.org/entity/Q38386726
Roads to the development of improved pertussis vaccines paved by immunologyA structure-function approach to optimizing TLR4 ligands for human vaccinesA proteomic approach to the development of DIVA ELISA distinguishing pigs infected with Salmonella Typhimurium and pigs vaccinated with a Salmonella Typhimurium-based inactivated vaccine.Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial VaccinesNovel approaches to Neisseria meningitidis vaccine design.Modulating endotoxin activity by combinatorial bioengineering of meningococcal lipopolysaccharide.Shotgun Analysis of Rough-Type Lipopolysaccharides Using Ultraviolet Photodissociation Mass SpectrometryOptimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics.Advances & challenges in leptospiral vaccine development.News Feature: The quest to solve sepsis.Diverse pro-inflammatory endotoxin recognition systems of mammalian innate immunity.
P2860

Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.

Item
http://www.wikidata.org/entity/Q38386726
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.
@en
type
label
Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.
@en
prefLabel
Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.
@en
P2093
P2860
P304
P31
P356
10.1586/14760584.2015.1026808
P433
P478
P50
P577
P698
P921